Plus: Rejoni secures $25M for uterine healing hydrogel, automated IVF lab launches in the US, and zuranolone shows sustained PPD improvement.
ARPA-H committed up to $90.7 million over four years to develop new fetal monitoring technology, creating opportunities for femtech innovators in diagnostics and fetal monitoring to replace 50-year-old technology. Separately, IVI RMA Global and Conceivable Life Sciences partnered to deploy the first automated IVF lab in the US, impacting femtech operators by integrating advanced automation into fertility treatment. This focus on technological advancements in both maternal health diagnostics and fertility care is reshaping clinical workflows. Five takes inside, plus a quick-hits roundup.
ARPA-H committed up to $34 million in the first year of a four-year, $90.7 million initiative to develop new fetal monitoring technology. Researchers will build a rapid point-of-care test for placental health to replace 50-year-old technology. This funding creates opportunities for femtech innovators in diagnostics and fetal monitoring.
Read the full story →Mila raised $2.5m in a pre-seed round to develop beauty-inspired intimate wellness products. Intu Diagnostics secured €1.1m to advance lab-free HPV testing, bringing its total funding to over €3m. Xella Health launched an AI platform for 130+ women’s health conditions, building on a $3.7m pre-seed round and a waitlist of over 15,000 women; Aeroflow Health also acquired maternal mental health platform Canopie. This activity points to continued investment and innovation across diverse women’s health solutions.
Read the full story →Rejoni raised $25 million in financing to prepare for the commercial launch of its first product, the Juveena Hydrogel System. Investors like ClavystBio and FemHealth Ventures participated. The Juveena Hydrogel System supports endometrial healing within the uterine cavity. This funding allows for the commercialization of new uterine health solutions for providers and patients.
Read the full story →IVI RMA Global and Conceivable Life Sciences partnered to deploy the first automated IVF lab in the US. This collaboration between the world's leading fertility care organization and Conceivable Life Sciences impacts femtech operators and clinicians by introducing advanced automation to fertility treatment.
Read the full story →Zuranolone reduced EPDS scores across all baseline PPD severities by Day 15 in a phase 4 real-world study with 191 participants. Improvements sustained through Day 45. This suggests new data supporting zuranolone's efficacy for maternal mental health.
Read the full story →